Long Ideas - Transcept Pharmaceuticals (NASDAQ:TSPT) has struggled to show compelling demand for its primary value driver, Intermezzo, which is marketed by partner, Purdue Pharmaceuticals in the U.S. … Continue Reading
Read NowLong Ideas - Despite closing a $26.1M private financing last Wednesday, shares of MethylGene (TSE:MYG) have yet to respond, but precedents suggest that MYG may be in for … Continue Reading
Read NowLong Ideas - Investors who choose to invest in speculative stocks often choose the biotechnology sector as their sector of choice. It’s easy to understand why; biotechnology companies … Continue Reading
Read NowLong Ideas - With the latest developments on the proposals to acquire Complete Genomics (NASDAQ:GNOM), investors have the chance to own shares of the life sciences company with … Continue Reading
Read NowLong Ideas - BGI-Shenzhen has extended the acceptance deadline for its $3.15 per share tender offer for Complete Genomics (NASDAQ:GNOM), but the elephant in the room – or … Continue Reading
Read NowLong Ideas - The biotechnology sector is no stranger to battleground stocks. Companies such as Dendreon (NASDAQ:DNDN) serve as solid examples of this fact. But perhaps no biotechnology … Continue Reading
Read NowLong Ideas - In the next several weeks, Keryx Biopharmaceuticals (KERX) will release results from 4 key Phase III trials for its primary drug candidate, Zerenex. The drug … Continue Reading
Read Now